Breaking News, Collaborations & Alliances

Generex Receives $700M Payment from Shenzhen BioScien

The upfront payment was for their license and research agreement focusing on Antigen Express AE37

Generex Biotechnology Corporation has confirmed its receipt of the $700,000 USD up-front license fee from Shenzhen BioScien Pharmaceuticals under a newly entered License and Research Agreement.  The purpose of the Agreement is to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in China (including Taiwan, Hong Kong, and Macau).   In addition to the license fee, Shenzhen BioScien will also make milestone payments to Generex of $1,000,000 USD...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters